William Schilling
Research Physician
Will is a research physician working at the Mahidol Oxford Tropical Medicine Research Unit (MORU), a specialty registrar in Infectious diseases and Microbiology in the UK. He is a DPhil student at the University of Oxford.
Will has been working at MORU since August 2019 and had focussed on research into community febrile illness. Since January 2020 and the appearance of COVID-19, he has turned his attention to potential therapies which may prevent infection with COVID-19, including two widely available drugs, chloroquine and hydroxychloroquine, that demonstrated promising in vitro effects against SARS-CoV-2. At the time of writing, the COVID-19 pandemic is worsening and there are no prophylactic agents nor vaccines or proven-effective treatments available. The aim is to rapidly determine if these, and other drugs, can be used as prophylactic agents against COVID-19.
Will has previous experience working in Medicine in Mbarara, Uganda.
Key publications
-
Evidence that remdesivir treatment reduces viral titers in patients with COVID-19.
Journal article
Boyd S. et al, (2024), Antimicrob Agents Chemother, 68
Recent publications
-
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV).
Journal article
Jittamala P. et al, (2025), EClinicalMedicine, 80
-
Evidence that remdesivir treatment reduces viral titers in patients with COVID-19.
Journal article
Boyd S. et al, (2024), Antimicrob Agents Chemother, 68
-
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Journal article
Schilling WHK. et al, (2024), PLoS Med, 21
-
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).
Journal article
Wongnak P. et al, (2024), Lancet Infect Dis, 24, 953 - 963
-
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)
Preprint
Jittamala P. et al, (2024)